Immune Health

The characterization study aims to quantify how long the biopolymer barrier persists in the nasal cavity — a critical c…

The dual-targeting CD19/CD20 mechanism marks a potential first-in-class approach, though the asset sits outside convent…

The allowances cover both composition-of-matter and method-of-use claims, strengthening IP position in the emerging inn…

The MHRA approval expands emergency allergy management options for a pediatric population where needle-based delivery h…

Celldex's anti-KIT monoclonal antibody moves the goalposts from symptom control to potential disease modification — a s…

The EAACI 2026 responder analysis adds to mounting evidence for targeted biologics in upper-airway inflammatory conditi…

Phase 3 APEX data presented at EHA 2026 positions the KIT-targeting agent as a potential standard-of-care option in a r…

Single-dose durability data from EHA 2026 positions off-the-shelf CAR-T as a potential paradigm shift in hematologic on…

TG Therapeutics advances to a potential registration-directed Phase 2 trial as subcutaneous delivery format targets imp…

Topline data from the randomized, double-blind LIBERTY study is expected in Q3 2026, alongside results from the pivotal…

The NMPA approval marks the first regulatory green light globally for a Sjögren's Disease-specific indication, spotligh…

The conditional approval marks a regulatory milestone for dual cytokine inhibition in a kidney disease with limited the…

Stay ahead of the industry